Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights  Fortress Biotech (NASDAQ: FBIO) reported Q3 2025 total net revenue of $17.6M, a 20.5% increase versus Q3 2024, driven largely by Journey Medical dermatology sales. Journey Medical net product revenue was $17.0M in the quarter vs. $14.6M a year earlier. Fortress reported consolidated net income of $3.7M ($0.13 basic, $0.11 diluted) versus a loss of $(15.0)M in Q3 2024. Consolidated cash totaled $86.2M as of Sept 30, 2025, up $28.9M year-to-date. Corporate updates include Sun Pharma's acquisition of Checkpoint (Fortress received ~$28M upfront plus potential CVR and a 2.5% royalty), dotinurad entering two Phase 3 trials, and an FDA CRL for CUTX-101 citing manufacturing (cGMP) observations with a planned resubmission.

#FBIO #FBIOP Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights 

www.stocktitan.net/news/FBIO/fortress-biote...

Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101 Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced that the U.S. Food and Drug Administration (“FDA”) has issued a Complete Response Letter (“CRL”) relating to the

#FBIO #FBIOP Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101

www.stocktitan.net/news/FBIO/fortress-biote...

Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights Fortress Biotech (NASDAQ:FBIO) reported significant Q2 2025 milestones and financial results. The company's subsidiary Checkpoint Therapeutics was acquired by Sun Pharma, generating ~$28 million upfront with potential for an additional $4.8 million CVR payment and 2.5% royalties on UNLOXCYT™ sales.Key highlights include: FDA acceptance of CUTX-101's NDA with PDUFA date of September 30, 2025, commercial launch of Emrosi™ for rosacea treatment with expanded payer coverage reaching 65% of U.S. commercial lives, and consolidated net revenue of $16.4 million in Q2 2025. The company reported net income of $13.4 million ($0.50 per share basic).Cash position strengthened to $74.4 million as of June 30, 2025, up from $57.3 million at end of 2024. Journey Medical's product revenues reached $15.0 million in Q2 2025.

#FBIO #FBIOP Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

www.stocktitan.net/news/FBIO/fortress-biote...

Fortress Biotech Earnings: Triple Win with $28M Checkpoint Deal, FDA Fast-Track, and Rosacea Drug Launch Q1 results reveal $91.3M cash position, Checkpoint acquisition by Sun Pharma, FDA priority review for Menkes disease drug, and successful Emrosi launch. Get details.

#FBIO #FBIOP Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

www.stocktitan.net/news/FBIO/fortress-biote...

Fortress Biotech Transforms Portfolio: Dual FDA Wins, $28M Deal, Latest Earnings Fortress lands FDA approvals for Emrosi and UNLOXCYT, secures $28M Sun Pharma deal, while streamlining operations. See full analysis of strategic transformation.

#FBIO #FBIOP Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights

www.stocktitan.net/news/FBIO/fortress-biote...

AI Breakthrough: Fortress Biotech's New Partnership Transforms Drug Development Process Fortress Biotech leverages Partex's AI platform to revolutionize drug asset evaluation, accelerating development pipeline while two approved drugs generate revenue.

#FBIO #FBIOP Partex and Fortress Biotech Announce Strategic Collaboration to Accelerate Asset Identification and Evaluation Using Proprietary AI Platform

www.stocktitan.net/news/FBIO/partex-and-for...

Fortress Biotech Launches Phase 2 Trial for Groundbreaking CMV Vaccine Triplex Fortress Biotech initiates NCI-funded Phase 2 trial of Triplex vaccine, targeting CMV infection prevention in stem cell transplant patients with promising immunity transfer approach.

#FBIO #FBIOP Fortress Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCT

www.stocktitan.net/news/FBIO/fortress-biote...

Fortress Biotech's CUTX-101 Gets FDA Priority Review for Rare Menkes Disease Treatment FDA accepts NDA for CUTX-101 with Priority Review, showing 80% reduction in mortality for Menkes disease. Could become first approved treatment with June 2025 PDUFA date.

#FBIO #FBIOP Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease

www.stocktitan.net/news/FBIO/fortress-biote...

#FBIO #FBIOP Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

www.stocktitan.net/news/FBIO/fortress-biote...

News; ( NASDAQ: #FBIOP ) (FBIOP) Investment Analysis and Advice

#StockMarket #News

NEWS: ( NASDAQ: #FBIOP ) How To Trade (FBIOP)

#StockMarket #News

BREAKING NEWS: ( NASDAQ: #FBIOP ) Fortress Biotech Reduces Total Debt and Enters into New $35 Million Term Loan with Oaktree with Maturity in 2027

#StockMarket #News